Goldman Sachs has published a research note titled "How Well Are UK & EU Stock Markets Working?" — a diagnostic exercise that places the two largest European equity pools under a single execution-quality lens.

The piece, available on goldmansachs.com, arrives as buy-side and sell-side desks contend with persistent fragmentation across lit order books, dark pools, periodic auctions and systematic internalisers. Any consolidated read on London-listed and EU-listed names carries direct weight for transaction-cost analysis, routing logic and best-execution files.

What does a market-quality review of this scope cover?

Execution teams benchmark regional liquidity against a standard set of inputs:

• Bid-ask spreads by market-cap cohort
• Touch liquidity and displayed depth at the top of book
• Turnover and venue-type share
• Volatility-adjusted implementation shortfall
• Off-exchange trading share under systematic internaliser waivers
• Listing trends, including IPO migration between New York, London and Amsterdam

A note that aggregates these metrics across the UK and EU in one frame gives desks a reference point against which to test internal TCA output and venue-selection logic.

Why the publication matters for routing decisions

European markets carry a stack of unresolved structural questions. The UK's listing regime review continues to reshape capital-raising choices. The MiFIR review-driven reforms to the equity trading rule book remain in implementation across the bloc, with the consolidated tape proposal still under negotiation.

Liquidity continues to redistribute between regulated markets, MTFs and SI venues. A research note that consolidates these threads into a single quality read becomes a working input for broker reviews, venue-selection committees and MiFID II Article 27 best-execution files.

The Goldman publication also enters a crowded field of public benchmarks. FESE publishes annual statistics across European exchanges. Trading venues disclose pre-trade and post-trade transparency data under MiFIR Articles 3, 4 and 8. Independent TCA providers run execution-quality league tables by venue and asset class. A new sell-side assessment competes for desk attention against all of those.

Broker-sold research, however, carries a different disclosure profile than independent TCA. Goldman Sachs Research operates under MiFID II research-unbundling rules, under which asset managers either pay separately for research or route it through a research-payment-account.

That payment classification does not change the diagnostic's content, but it changes how asset managers book the cost against their research budgets — a small but real line item in any TCA workflow.

What to verify before acting on the note

Execution leads should weigh the Goldman assessment against their own venue analytics. The diagnostic's weight for routing decisions depends on three questions:

1. Does it break out results by market cap, sector and venue type?
2. Does it quantify the gap between best-execution policy and realised execution quality?
3. Does it identify which venue types absorbed volume shifts, and at what cost?

Without access to the underlying tables in the publicly available version, desks should treat the Goldman headlines as a starting point, not a substitute, for internal analytics.

What the note leaves unanswered

Goldman has not announced a publication cadence for this line of research. Desks tracking the note for revisions or follow-on work will need to monitor the firm's research portal directly.

The note's value to the execution community will rise or fall on whether future updates add cross-asset context — fixed income, ETFs, derivatives — or remain confined to cash equities.

The publication sets a benchmark against which subsequent European market-quality research will be read; the next test for execution teams is whether it changes order allocation across UK and EU venues.